AstraZeneca vs BBVA: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and BBVA side by side

1. 1857BBVA

   Banco de Bilbao is created

   Bilbao's Board of Trade promotes the creation of Banco de Bilbao as a bank of issue and discount for the city's merchants. It is the oldest institution in BBVA's corporate line.

2. 1901BBVA

   Banco de Vizcaya is founded

   Banco de Vizcaya is founded in Bilbao and grows alongside Banco de Bilbao as the second large Basque bank, financing regional industry.

3. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

4. 1988BBVA

   Banco de Bilbao and Banco de Vizcaya merge

   The two Basque rivals merge to form Banco Bilbao Vizcaya (BBV), one of the largest banks in Spain ahead of the European single market.

5. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

6. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

7. 1999BBVA

   BBV merges with Argentaria to create BBVA

   BBV merges with Argentaria, the group Spain had assembled from state-owned lenders such as Banco Exterior, Banco Hipotecario and Caja Postal, forming Banco Bilbao Vizcaya Argentaria.

8. 2000AstraZeneca

   Nexium Launch Replaces Prilosec

   AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

9. 2000BBVA

   BBVA takes control of Bancomer in Mexico

   BBVA capitalizes Bancomer with USD1.4 billion and merges it with BBV-Probursa to create Grupo Financiero BBVA Bancomer, the largest bank in Mexico.

10. 2004BBVA

    BBVA bids for the rest of BBVA Bancomer

    BBVA offers USD4.1 billion in cash for the roughly 41 percent of BBVA Bancomer held by minority investors, ending with about 99 percent of the Mexican group.

11. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

12. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

13. 2007BBVA

    Compass Bancshares purchase builds a US franchise

    BBVA buys Compass Bancshares of Birmingham, Alabama for USD9.6 billion, creating a Sunbelt retail bank that later traded as BBVA Compass and BBVA USA.

14. 2010BBVA

    BBVA agrees to buy 24.9 percent of Garanti

    BBVA agrees to pay ~$4.74 billion (EUR4.195 billion), about USD5.84 billion, for 24.9 percent of Turkiye Garanti Bankasi, funded with a rights issue of about $5.65 billion (EUR5 billion).

15. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

16. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

17. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

18. 2014BBVA

    BBVA wins the auction for Catalunya Banc

    BBVA bids ~$1.34 billion (EUR1.187 billion) for Catalunya Banc, with 1.5 million customers and ~$71.2 billion (EUR63 billion) of assets, in the auction run by Spain's bank restructuring fund. The deal closed in 2015.

19. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

20. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

21. 2018BBVA

    Onur Genc is named CEO

    BBVA's board designates Onur Genc as chief executive from December 31, 2018, the date Carlos Torres Vila replaces Francisco Gonzalez as executive chairman.

22. 2019BBVA

    BBVA unifies its brand worldwide

    The group drops local names such as BBVA Bancomer, BBVA Francés, BBVA Continental and BBVA Compass and operates as BBVA in every market.

23. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

24. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

25. 2021BBVA

    BBVA closes the transfer of BBVA USA to PNC

    BBVA completes the transfer of BBVA USA Bancshares to PNC Financial Services on June 1, 2021, receiving about USD11.5 billion, equivalent to ~$10.8 billion (EUR9.6 billion), in cash.

26. 2022BBVA

    Tender offer lifts the Garanti stake to 85.97 percent

    A tender offer at 15 Turkish lira per share closes in May 2022 and raises BBVA's holding in Garanti BBVA to 85.97 percent.

27. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

28. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

29. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

30. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

31. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

32. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

33. 2025BBVA

    The offer for Banco Sabadell lapses

    Shareholders representing 25.47 percent of Sabadell's voting rights accept BBVA's all-share offer, short of the minimum BBVA required, and the bid lapses on October 16, 2025.

34. 2025BBVA

    Record net attributable profit of ~$11.9B (EUR10.511B)

    BBVA reports gross income of ~$41.7B (EUR36.931B) and net attributable profit of ~$11.9B (EUR10.511B) for 2025, with ROTE of 19.3 percent and an efficiency ratio of 38.8 percent.

35. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

36. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

37. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

38. 2026BBVA

    BBVA is ordered to stand trial in the Villarejo case

    Spain's National Court orders BBVA, former chairman Francisco Gonzalez and 14 other defendants to stand trial over work commissioned from former police commissioner Jose Manuel Villarejo between 2004 and 2016.

Acquisitions

Questions about AstraZeneca vs BBVA